Tebentafusp, sold under the brand name Kimmtrak, is an anti-cancer medication used to treat uveal melanoma. Tebentafusp is a bispecific gp100 peptide-HLA-directed CD3 T cell engager. Tebentafusp is given by intravenous infusion. From Wikipedia
The pioneering drug Tebentafusp, approved by NICE, offers hope to patients with metastatic uveal melanoma by extending survival and stabilizing the disease.
